IQVIA (NYSE:IQV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

IQV has been the topic of a number of other research reports. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Mizuho lifted their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Evercore ISI lifted their price target on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Finally, Truist Financial reiterated a “buy” rating and set a $265.00 price target (up previously from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $239.94.

IQVIA Stock Performance

Shares of IQVIA stock opened at $213.82 on Friday. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $225.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a market capitalization of $36.41 billion, a P/E ratio of 29.33, a P/E/G ratio of 2.42 and a beta of 1.34. The company’s 50 day moving average price is $197.64 and its two-hundred day moving average price is $174.62.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter last year, the business posted $2.84 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Canada Pension Plan Investment Board increased its stake in IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after purchasing an additional 312,807 shares in the last quarter. Alliancebernstein L.P. increased its stake in IQVIA by 0.6% in the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership bought a new stake in IQVIA in the second quarter valued at $515,772,000. JPMorgan Chase & Co. increased its stake in IQVIA by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in IQVIA by 12.3% in the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.